Nanoscale insights into the local structural rearrangements of amyloid-β induced by bexarotene-Reference-Cited by-同舟云学术

Nanoscale insights into the local structural rearrangements of amyloid-β induced by bexarotene

Published:2023 Issue:35 Volume:15 Page:14606-14614
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Sofińska Kamila¹^ORCID,Batys Piotr²^ORCID,Cernescu Adrian³,Ghosh Dhiman⁴,Skirlińska-Nosek Katarzyna¹⁵,Barbasz Jakub²,Seweryn Sara¹⁵,Wilkosz Natalia¹⁶,Riek Roland⁴,Szymoński Marek¹,Lipiec Ewelina¹^ORCID

Affiliation:

1. Jagiellonian University, Faculty of Physics, Astronomy and Applied Computer Science, M. Smoluchowski Institute of Physics, Łojasiewicza 11, 30-348 Krakow, Poland

2. Jerzy Haber Institute of Catalysis and Surface Chemistry, Polish Academy of Sciences, Niezapominajek 8, 30-239 Krakow, Poland

3. Attocube Systems AG, Eglfinger Weg 2, 85540 Haar, Germany

4. ETH Zürich, Laboratory of Physical Chemistry, 8093 Zürich, Switzerland

5. Jagiellonian University, Doctoral School of Exact and Natural Sciences, Krakow, Poland

6. AGH University of Science and Technology, Faculty of Physics and Applied Computer Science, Reymonta 19, 30-059 Krakow, Poland

Abstract

We report on the influence of aggregation suppressor on the secondary structure of amyloid-β species. The applied multimodal approach combining nanospectroscopic studies and molecular dynamics enabled to follow the interaction between the aggregating amyloid-β and a small molecule drug.

Funder

Polska Akademia Nauk

Infrastruktura PL-Grid

Narodowe Centrum Nauki

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2023/NR/D3NR01608K

Reference55 articles.

1. Defeating Alzheimer's disease and other dementias: a priority for European science and society

2. Tau-targeting therapies for Alzheimer disease

3. Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis

4. Small-molecule conversion of toxic oligomers to nontoxic β-sheet–rich amyloid fibrils

5. Amyloid beta: structure, biology and structure-based therapeutic development